Kodiak Sciences Announces Presentation of Durability Data from Clinical Development Program of KSI-301 in Wet AMD, DME, and RVO at AAO
Kodiak Sciences announced that Charles C. Wykoff, MD, PhD, will present first-time results at the annual mneeting of the American Academy of Ophthalmology (AAO) to be held in San Francisco. The Retina Subspecialty Day (October 11-12) will feature a presentation of emerging data from the phase 1b clinical study of KSI-301 in treatment-naïve patients with neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
“We were very pleased with the early durability data from patients with wet AMD treated with KSI-301 in our phase 1b clinical study announced last month at The Retina Society Annual Meeting. Those data underscored our belief in the potential for KSI-301 to be a leading, next-generation anti-VEGF with a long-interval durability profile,” Victor Perlroth, MD, Chief Executive Officer of Kodiak Sciences, said in a company news release. “We look forward to building on those initial results with Dr. Charles Wykoff’s upcoming presentation at the AAO Retina Subspecialty Day, where new data will be shown on the efficacy, safety and durability of KSI-301 in wet AMD, as well as DME and RVO. These are the three diseases most commonly treated with intravitreal anti-VEGF therapies. We look forward to further engaging with the community about the new data and our planning for the clinical development of KSI-301.”
Details of the presentation are as follows:
Oral Presentation: Extended Durability in Exudative Retinal Diseases Using the Novel Intravitreal Anti-VEGF Antibody Biopolymer Conjugate KSI-301: Results from the Phase 1b Study in Patients with wAMD, DME and RVO
Presenter: Charles C. Wykoff, MD, PhD – Retina Consultants of Houston, Houston, TX
Presentation date and time: Friday, October 11, 2019 – 4:58pm PT
The slide presentation will be available on the Kodiak Investor Relations website at http://ir.kodiak.com/ at the time of the presentation.